Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5640 | 2021 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2903 | 2020 |
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1766 | 2020 |
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1404 | 2021 |
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Y Peng, AJ Mentzer, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai, ... Nature immunology 21 (11), 1336-1345, 2020 | 1273 | 2020 |
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load P Kiepiela, K Ngumbela, C Thobakgale, D Ramduth, I Honeyborne, ... Nature medicine 13 (1), 46-53, 2007 | 1248 | 2007 |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 981 | 2022 |
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation RK Gupta, S Abdul-Jawad, LE McCoy, HP Mok, D Peppa, M Salgado, ... Nature 568 (7751), 244-248, 2019 | 737 | 2019 |
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease JF Rahier, S Ben-Horin, Y Chowers, C Conlon, P De Munter, G D'Haens, ... Journal of Crohn's and Colitis 3 (2), 47-91, 2009 | 702 | 2009 |
Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc, D Zhou, HM Ginn, ... Cell 185 (14), 2422-2433. e13, 2022 | 676 | 2022 |
Adaptation of HIV-1 to human leukocyte antigen class I Y Kawashima, K Pfafferott, J Frater, P Matthews, R Payne, M Addo, ... Nature 458 (7238), 641-645, 2009 | 564 | 2009 |
Early and nonreversible decrease of CD161++/MAIT cells in HIV infection C Cosgrove, JE Ussher, A Rauch, K Gärtner, A Kurioka, MH Hühn, ... Blood, The Journal of the American Society of Hematology 121 (6), 951-961, 2013 | 368 | 2013 |
HIV-1 DNA predicts disease progression and post-treatment virological control JP Williams, J Hurst, W Stöhr, N Robinson, H Brown, M Fisher, S Kinloch, ... elife 3, e03821, 2014 | 332 | 2014 |
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison M Ainsworth, M Andersson, K Auckland, JK Baillie, E Barnes, S Beer, ... The Lancet Infectious Diseases 20 (12), 1390-1400, 2020 | 320 | 2020 |
European Crohn’s and Colitis Organisation (ECCO) JF Rahier, F Magro, C Abreu, A Armuzzi, S Ben-Horin, Y Chowers, ... Second European evidence-based consensus on the prevention, diagnosis and …, 2014 | 308 | 2014 |
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine RP Payne, S Longet, JA Austin, DT Skelly, W Dejnirattisai, S Adele, ... Cell 184 (23), 5699-5714. e11, 2021 | 299 | 2021 |
Selection bias at the heterosexual HIV-1 transmission bottleneck JM Carlson, M Schaefer, DC Monaco, R Batorsky, DT Claiborne, J Prince, ... Science 345 (6193), 1254031, 2014 | 296 | 2014 |
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report RK Gupta, D Peppa, AL Hill, C Gálvez, M Salgado, M Pace, LE McCoy, ... The Lancet HIV 7 (5), e340-e347, 2020 | 250 | 2020 |
Short-course antiretroviral therapy in primary HIV infection SPARTAC Trial Investigators New England Journal of Medicine 368 (3), 207-217, 2013 | 245 | 2013 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 237 | 2021 |